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Variations in cord blood manufacturing and administration are common, and the optimal practice is not
known. We compared processing and banking practices at 16 public cord blood banks (CBB) in the United
States and assessed transplantation outcomes on 530 single umbilical cord blood (UCB) myeloablative
transplantations for hematologic malignancies facilitated by these banks. UCB banking practices wereedgments on page 694.
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Processing methods
Survivalseparated into 3 mutually exclusive groups based on whether processing was automated or manual, units
were plasma and red blood cell reduced, or buffy coat production method or plasma reduced. Compared with
the automated processing system for units, the day 28 neutrophil recovery was signiﬁcantly lower after
transplantation of units that were manually processed and plasma reduced (red cell replete) (odds ratio, .19;
P ¼ .001) or plasma and red cell reduced (odds ratio, .54; P ¼ .05). Day 100 survival did not differ by CBB.
However, day 100 survival was better with units that were thawed with the dextran-albumin wash method
compared with the “no wash” or “dilution only” techniques (odds ratio, 1.82; P ¼ .04). In conclusion, CBB
processing has no signiﬁcant effect on early (day 100) survival despite differences in kinetics of neutrophil
recovery.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Umbilical cord blood (UCB) transplantation has extended
access to hematopoietic stem cell transplantation (HCT) to a
diverse racial and ethnic population [1]. Recent data have
suggested comparable results between UCB and grafts from
matched adult unrelated donors in both the myeloablative
and reduced-intensity transplantation setting [2-5]. How-
ever, unlike bone marrow or peripheral blood, UCB units are
collected, cryopreserved, and, when needed, thawed and
infused.
Although the Food and Drug Administration has issued
guidance for manufacturing of cord blood for banking for
unrelated transplantation, and the American Association of
Blood Banks and the Foundation for Accreditation of
Cellular Therapy have established standards for product
manufacturing, practices at individual cord blood banks
(CBB) vary tremendously. For example, UCB can either be
collected in utero by trained obstetrical personnel and/or ex
utero by trained staff of the UCB bank. The American Red
Cross reported no difference in total nucleated cell (TNC)
count, postprocessing CD34þ, or colony-forming units be-
tween the 2 methods, but transplantation outcomes were
not assessed [6]. Similarly, processing of the UCB unit varies
widely among and within the CBBs. In the earliest years of
UCB banking, CBBs did not manipulate the product, other
than diluting and adding dimethyl sulfoxide (DMSO), before
freezing [7]. Today, most CBBs employ some form of volume
reduction, which is generally achieved by depleting red
blood cells, plasma, or both [8]. Each CBB has its own pro-
cedures, some of which may have evolved over the history of
the bank. Most CBBs have adopted the plasma and red blood
cell reduction method [9]. An alternative method is to
deplete plasma but not red blood cells so that entrapment of
nucleated cells, and possibly progenitor and stem cells, is
avoided, with some degree of volume reduction associated
with the removal of plasma [10,11].
Appropriate handling and thawing of UCB units at
transplantation centers are equally important to successful
transplantation outcomes. Pablo Rubinstein described a
thawing procedure using a dextran and albumin solution to
remove DMSO. The majority of transplantation centers
adopted this approach, and nucleated cell count recoveries of
75% to 90% have been reported [12,13]. More recently, Barker
et al. described a dilution-only “no wash” method with
reconstitution in dextran-albumin for a ﬁnal 5% DMSO con-
centration [14]. Nucleated cell count recovery was 86%, and
there were no serious adverse infusion events. Finally, some
centers have used a nonvolume-reduced (unmanipulated)
thawing strategy and have demonstrated adequate engraft-
ment [15]. The report of several life-threatening infusion
reactions with UCB infusion have intensiﬁed the need to
determine the optimal thawing practice [16].The optimal processing techniques for UCB units are not
established and whether transplantation outcomes differ by
techniques is not clear. Therefore, we collected information
on UCB processing at the CBBs and examined the data for an
effect of processing methods at CBBs in patients who had
undergone a single UCB transplantation for acute leukemia
or myelodysplastic syndrome, the most common indications
for allogeneic HCT. This report, the ﬁrst of its kind, provides
additional knowledge on whether practices at CBBs tech-
niques inﬂuence hematopoietic recovery and early survival
after UCB transplantation.
MATERIALS AND METHODS
Data Source
The Center for International Blood and Marrow Transplant Research
(CIBMTR) is a working group of over 450 transplantation centers worldwide
that contribute detailed data on consecutive allogeneic and autologous HCT
to a statistical center at the Medical College of Wisconsin or the data coor-
dinating center at the National MarrowDonor Program. Banking practices at
CBBs were obtained using a short survey, which addressed UCB unit pro-
cessing at the banks. Data on UCB unit thawing at transplantation centers
were obtained through standardized data collection forms developed by the
CIBMTR. Patients provide written informed consent for participation in
accordance with the Declaration of Helsinki. The institutional review boards
of the Medical College of Wisconsin and the National Marrow Donor Pro-
gram approved the study.
Patients
Included are 530 patients with acute myeloid leukemia (AML), acute
lymphoid leukemia or myelodysplasia who received single unit unrelated
UCB transplantation in the United States with a UCB unit from 1 of the 16
participating CBBs. All transplantations occurred in the United States be-
tween the years 2000 and 2011. Only recipients of myeloablative regimens,
deﬁned as having received total body irradiation dose of 1000 cGy or higher
or busulfan dose greater than 9 mg/kg or melphalan dose greater than
150 mg/m2, are included [17]. Recipients of multiple or expanded UCB units,
reduced-intensity conditioning regimens, and transplantations for nonma-
lignant diseases were excluded.
CBB Practices
Sixteen publically funded CBBs in the United States participated in the
survey. Using banking practices reported, 3 mutually exclusive groups were
created (Table 1) based on the following: automated ormanual processing at
the CBB andwhether units were plasma and red blood cell reduced, used the
buffy coat production method, or were plasma reduced. All units contained
DMSO and an hyperosmolar agent. Group 1 included units that were pro-
cessed using an automated method that were plasma and red blood cell
reduced (n¼ 84) or used the buffy coat productionmethod (n¼ 34). Group 2
included manually processed units that were plasma and red blood cell
reduced (n¼ 274) or used the buffy coat productionmethod (n¼ 5). Group 3
includedmanually processed units that were plasma reduced. Of note, as the
groups were created based on self-reported practices, some CBBs are rep-
resented in more than 1 group, as banking practices evolved over the study
period. Further, group 3 represents a single CBB and the buffy coat pro-
duction method is implemented at 3 CBBs and represented in group 1
(n ¼ 34 from a single CBB) and group 2 (n ¼ 5 from 2 CBBs).
Outcomes
The primary endpoint was hematopoietic recovery; neutrophil recovery
was deﬁned as achieving an absolute neutrophil count  .5  109/L for 3
Table 1
Cord Bank Practices
Characteristic Group 1 Group 2 Group 3
Practices Automated processing, plasma
and red cell reduced or buffy
coat production method
Manual processing, plasma and
red cell reduced or buffy coat
production method
Manual processing,
plasma reduction
No. of banks* 6 13 1
Type of processing system
Automated 6
Manual 13 1
Product processing method at banks
Plasma and red cell reduction 5 11
Buffy coat production 1 2
Plasma reduction 1
Anticoagulant
ACD 1
CPD 4 12 1
CPDA 1 1
Storage method at bank
Vapor phase 1 6 1
Liquid nitrogen 5 8
Years of existence of bank
10 yr 2 2
11-15 yr 2 7 1
15-20 yr 2 4
ACD indicates acid citrate dextrose; CPD, citrate phosphate dextrose; CPDA, citrate phosphate adenine.
* Number of banks exceeds N ¼ 16 because practice changes occurred over time and those banks are represented in the Table more than once.
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unsupported for 7 days. Death from any cause was considered an event.
Statistical Methods
The characteristics of patients, their disease, and transplantation
grouped according to CBB practice were compared using the chi-square test
for categorical variables [18]. The incidences of neutrophil and platelet re-
covery were calculated using the cumulative incidence estimator; death
without an event was considered a competing risk [19]. The day 100
probability of overall survival was calculated using the Kaplan-Meier esti-
mator [18]. Generalized linear mixed models were used to ﬁt random effect
logistic regression models for day 28 and day 42 neutrophil, day 90 platelet
recovery, and day 100 overall survival. These models included random ef-
fects for CBB and for transplantation center to account for within bank or
within center correlation when examining CBB-speciﬁc variables or trans-
plantation centerespeciﬁc variables [20]. The following variables were
tested in a multivariate analysis: CBB practice groups (1, 2, and 3) and its
effect on outcomes was the primary interest. Consequently, the variable for
CBB practice group was held in all steps of model building, regardless of the
level of signiﬁcance attained. Other CBB variables tested included vapor
versus liquid storage, year of collection (1996 through 1999 versus 2000
through 2005 versus 2006 through 2011), and length of existence of the CBB
(10 versus 11 through 15 versus > 15 years). Transplantation center
practice was tested as follows: no DMSO dilution/no wash versus reconsti-
tution in dextran/plasmalyte A and interval between thaw and completion
of infusion (<2 versus 2 through 4 versus > 4 hours). In addition to CBB
practice and transplantation center practices, patient (age, gender, perfor-
mance score, cytomegalovirus serostatus, race), disease, disease status at
transplantation, and transplantation characteristics (conditioning regimen,
in vivo Tcell depletion, graft-versus-host disease prophylaxis, HLAmatch [6/
6 versus 5/6 versus 4/6], TNC dose [< 3 versus 3 to 5 versus > 5  107/kg],
donor-recipient race match [donor/recipient same race versus other], in-
terval between unit collection and transplantation [< 1 versus 1 through 3
versus > 3 through 5 versus > 5 years], and transplantation period [2000
through 2004 versus 2005 through 2011]) were tested in all multivariate
models such that the effects of CBB and transplantation center practice were
adjusted for known clinical characteristics associated with outcome. A P
value of .05 or less was considered signiﬁcant; all P values were 2-sided.
Analyses were performed with SAS 9.3 (Cary, NC).
RESULTS
Patient, Disease, and Transplantation Characteristics
Table 2 shows the characteristics of the 530 patients
grouped by processing methods at the CBBs. Overall, the
characteristics of patients, their diseases, and trans-
plantations were similar across the 3 groups except forpatient race, TNC, thaw procedures at transplantation cen-
ters, transplantation conditioning regimen, in vivo T cell
depletion, planned growth factor treatment, and trans-
plantation period. Caucasians were less likely to have
received units that were manually processed and plasma
reduced. The manually processed units were more likely to
contain prefreeze TNC greater than 5107/kg but there were
no differences in post-thaw TNC recovery between the 3
groups. During the thawing process, the automated pro-
cessed units, which account for the more recent trans-
plantations, were less likely to have been washed and
reconstituted in dextran. Total body irradiation trans-
plantation conditioning regimens were more commonly
used in patients who received units that were processed
using an automated technique. On the other hand, in vivo T
cell depletion was common with manually processed units
and reﬂect clinical practice in an earlier period. Planned
growth factor therapy was less common for units that were
manually processed and plasma reduced.Neutrophil and Platelet Recovery
The primary endpoint of the study was hematopoietic
recovery: day 28 neutrophil recovery and day 90 platelet
recovery (Table 3). The likelihood of neutrophil recovery was
lower after transplantation of UCB units that were processed
manually and plasma reduced (red blood cell replete) or
plasma and red cell depleted (Table 3, Figure 1). Further,
neutrophil recovery was lower after transplantation of
manually processed units with plasma reduction compared
with plasma and red cell reduction (odds ratio, .34; 95%
conﬁdence interval [CI], .16 to .74; P ¼ .04). The day 28 cu-
mulative incidence of neutrophil recovery was 40% (95% CI,
32% to 48%) after transplantation of UCB units that were
processed manually and plasma reduced; median time to
recovery was 29 days. Corresponding probabilities for units
that were processed using automated and manual methods
with plasma and red blood cell reduction or buffy coat pro-
duction method were 77% (95% CI, 69% to 84%) and 68% (95%
CI, 63% to 73%), respectively; median time to neutrophil
Table 2
Patients, Disease, Transplantation, and Transplantation Center Practices
Variable Group 1 Group 2 Group 3 P Value
Description Automated processing, plasma
and red cell reduced or buffy
coat production method
Manual processing, plasma and
red cell reduced or buffy coat
production method
Manual processing,
plasma reduced
No. of patients 118 279 133
Age .47
16 yr 89 (75) 225 (81) 107 (80)
>16 yr 29 (25) 54 (19) 26 (20)
Sex .76
Male 55 (47) 141 (51) 67 (50)
Female 63 (53) 138 (46) 66 (50)
Performance score .21
<90 20 (17) 51 (18) 33 (25)
90-100 97 (82) 218 (78) 97 (73)
Not reported 1 (<1) 10 (4) 3 (2)
Recipient CMV serostatus .06
Negative 46 (39) 137 (49) 53 (40)
Positive 71 (60) 137 (49) 79 (59)
Not reported 1 (<1) 5 (1) 1 (1)
Recipient race <.001
Caucasian 61 (52) 181 (65) 55 (41)
Non-Caucasian 57 (48) 92 (33) 77 (58)
Not reported 0 6 (2) 1 (<1)
Disease status at transplantation .02
CR1/RA 52 (44) 92 (33) 53 (40)
CR2 53 (45) 127 (46) 48 (36)
Relapse/RAEB 13 (11) 60 (21) 32 (24)
Conditioning regimen .04
TBI-containing 96 (81) 193 (69) 100 (75)
Non-TBI containing 22 (19) 86 (31) 33 (25)
GVHD prophylaxis .26
Tacrolimus-containing 33 (28) 77 (28) 47 (35)
Cyclosporine-containing 83 (70) 199 (71) 85 (64)
Other 2 (2) 3 (1) 1 (1)
HLA match low resolution at A, B, and
allele-level DRB1
.42
4/6 42 (36) 88 (32) 55 (41)
5/6 57 (48) 141 (51) 58 (44)
6/6 19 (16) 50 (17) 20 (15)
Donor-recipient race match .02
Donor recipient same race 71 (60) 150 (54) 70 (53)
Donor recipient different race 47 (40) 72 (26) 62 (47)
Unknown 0 57 (20) 1 (1)
In vivo T depletion <.001
No 76 (64) 116 (42) 58 (44)
Yes 42 (36) 163 (58) 75 (56)
TNC dose (107/kg)
3.0 11 (9) 32 (11) 17 (13) .01
3.0-5.0 44 (37) 74 (27) 24 (18)
>5.0 61 (52) 172 (62) 92 (69)
Not reported 2 (2) 1 (<1) 0
Post-thaw TNC recovery .77
<70% 21 (18) 56 (20) 27 (20)
70%-90% 53 (45) 120 (43) 62 (47)
>90% 23 (19) 67 (24) 28 (21)
Not reported 21 (18) 36 (13) 16 (12)
Thawing method at transplantation center <.001
No wash/DMSO dilution 44 (37) 42 (15) 24 (18)
Washed, reconstituted in dextran/hespan/
plasmalyte
71 (60) 219 (78) 95 (71)
Not reported 3 (3) 17 (7) 14 (11)
Interval between thaw to completing of
infusion
.62
<2 hr 38 (32) 91 (33) 45 (34)
2-4 hr 56 (47) 127 (46) 56 (42)
>4 hr 11 (9) 32 (11) 22 (17)
Not reported 13 (11) 29 (10) 10 (8)
Interval from unit collection to
transplantation
<.001
1 yr 27 (23) 22 (8) 21 (16)
1-3 yr 64 (54) 97 (35) 48 (36)
3-5 yr 19 (16) 76 (27) 33 (25)
>5 yr 8 (7) 84 (30) 31 (23)
(Continued on next page)
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Table 2
(continued)
Variable Group 1 Group 2 Group 3 P Value
Planned growth factor therapy .02
None 34 (29) 87 (31) 60 (45)
Yes 68 (58) 152 (54) 52 (39)
Not reported 16 (14) 40 (15) 21 (16)
Year of transplantation <.001
2000-2004 6 (5) 57 (20) 21 (16)
2005-2011 112 (95) 222 (80) 112 (84)
CMV indicates cytomegalovirus; CR, complete remission; RA, refractory anemia; RAEB, refractory anemia with excess blasts; TBI, total body irradiation; GVHD,
graft-versus-host disease.
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processing methods, the likelihood of neutrophil recovery
was higher after transplantation of units with TNC greater
than 5  107/kg compared with units with TNC < 3  107/kg
and older patients (Table 3). Despite early differences in re-
covery rates, by 6 weeks after transplantation, there were no
appreciable differences between the 3 groups (Table 3).
There was no difference in platelet recovery at day 90
among the 3 groups (Table 3). The day 90 probabilities ofTable 3
Risk Factors Associated with Neutrophil Recovery at Day 28 and Day 42 Platelet R
Risk Factor N1/N2
Neutrophil recovery at day 28
Banking practice*
Group 1 92/116
Group 2 188/270
Group 3 60/132
Age
16 yr 269/412
>16 yr 71/106
TNC dose,  107/kg
3 31/58
>3-5 89/140
>5 220/320
Neutrophil recovery at day 42
Group 1 104/116
Group 2 225/270
Group 3 108/132
TNC dose,  107/kg
3 40/58
>3-5 117/140
>5 280/320
Conditioning regimen
TBI þ cyclophosphamide 327/379
Busulfan þ cyclophosphamide 110/139
Platelet recovery at day 90
Group 1 76/116
Group 2 171/270
Group 3 69/132
Gender
Female 145/260
Male 171/258
TNC dose,  107/kg
3 23/58
>3-5 88/140
>5 205/320
Disease statusy
Early 128/193
Intermediate 141/222
Advanced 47/103
N1 indicates number of events; N2, number evaluable.
Odds ratios>1 indicate better outcome. Other comparisons include day 28 neutrop
day 42 neutrophil recovery (group 3 versus group 2; OR, .81 [95% CI, .47 to 1.42]
* Group 1: automated processing, units were plasma and red blood cell reduced
plasma and red blood cell reduced or buffy coat production method. Group 3: m
y Early risk includes patients in ﬁrst complete remission/refractory anemia. Int
includes patients in relapse/refractory anemia with excess blasts.platelet recovery were 65% (95% CI, 57% to 74%), 64% (95% CI,
58% to 69%), and 53% (95% CI, 44% to 61%) for groups 1, 2, and
3 respectively. The median time to platelet recovery was 46,
48, and 61 days, respectively. Additionally, platelet recovery
was better after transplantation of units with TNC greater
than 5  107/kg compared with units with TNC 3  107/kg or
lower and in males compared with females. Platelet recovery
was lower in patients who underwent transplantation with
active disease compared with those who underwentecovery at Day 90
Odds Ratio (95% CI) P Value
1.00
.54 (.29-1.00) .05
.19 (.08-.44) <.001
1.00
2.01 (1.11-3.67) .02
1.00
1.65 (.82-3.31) .16
3.26 (1.57-6.77) .002
1.00
.61 (.31-1.21) .16
.50 (.23-1.06) .07
1.00
2.11 (1.03-4.33) .04
3.74 (1.90-7.35) <.001
1.00
.52 (.30-.88) .02
1.00
.98 (.61-1.58) .93
.61 (.36-1.05) .08
1.00
1.58 (1.09-2.28) .02
1.00
2.43 (1.27-4.66) .008
2.64 (1.46-4.78) .002
1.00
.82 (.54-1.25) .36
.45 (.27-.75) .002
hil recovery (group 3 versus group 2; OR, .34 [95% CI, .16 to .74], P¼ .04) and
, P ¼ .46).
or buffy coat production method. Group 2: manual processing, units were
anual processing, units were plasma reduced.
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Figure 2. Overall survival. Group 1: automated processing, units were plasma
and red blood cell reduced or buffy coat production method. Group 2: manual
processing, units were plasma and red blood cell reduced or buffy coat pro-
duction method. Group 3: manual processing, units were plasma reduced.
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Figure 1. Neutrophil recovery. Group 1: automated processing, units were
plasma and red blood cell reduced or buffy coat production method. Group 2:
manual processing, units were plasma and red blood cell reduced or buffy coat
production method. Group 3: manual processing, units were plasma reduced.
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disease status on platelet recovery was independent of CBB
processing methods.
Of note, we carefully examined for an effect of duration of
storage UCB units and its effect on hematopoietic recovery.
Neutrophil recovery at day 28 and day 42 was not associated
with duration of storage (P ¼ .87 and P ¼ .51, respectively).
Similarly, platelet recovery at day 90 was also not associated
with duration of storage of UCB units (P ¼ .89).Overall Survival
Despite a lower threshold of early neutrophil recovery
after transplantation of manually processed units, therewere
no differences among the groups with respect to overall
survival at day 100 (Table 4, Figure 2). The day 100 survival
probabilities for groups 1, 2, and 3 were 83% (95% CI, 76% toTable 4
Risk factors Associated with Overall Survival at Day 100
Risk Factor N1/N2 Odds Ratio
(95% CI)
P Value
Banking practice*
Group 1 96/116 1.00
Group 2 218/270 .94 (.51-1.73) .85
Group 3 106/132 .93 (.47-1.84) .84
Gender
Female 199/260 1.00
Male 221/258 1.84 (1.16-2.91) .01
Disease statusy
Early 165/193 1.00
Intermediate 183/222 .82 (.48-1.40) .47
Advanced 72/103 .44 (.24-.80) .007
Unit processing at
transplantation center
No wash/DMSO dilution 84/108 1.00
Thaw/wash þ dextran
reconstitution
314/376 1.82 (1.02-3.23) .04
Transplantation period
2000-2004 61/83
2005-2011 359/435 2.06 (1.14-3.72) .02
N1 indicates number alive; N2, number evaluable.
Odds ratios >1 indicate better outcome.
* Group 1: automated processing, units were plasma and red blood cell
reduced or buffy coat production method. Group 2: manual processing,
units were plasma and red blood cell reduced or buffy coat production
method. Group 3: manual processing, units were plasma reduced.
y Early risk includes patients in ﬁrst complete remission/refractory ane-
mia. Intermediate risk includes patients in second complete remission.
Advanced risk includes patients in relapse/refractory anemia with excess
blasts.89%), 82% (95% CI, 74% to 88%), and 80% (95% CI, 73% to 87%),
respectively. However, there were other factors associated
with early survival that were independent of CBB processing
methods. Survival was higher for males, for transplantations
in patients in ﬁrst complete remission/refractory anemia,
and transplantations after 2004. Independent of CBB prac-
tice, thawing practice at transplantation centers also
inﬂuenced early survival; survival was higher after trans-
plantation of units that were thawed, washed, and recon-
stituted in dextran compared with units that were not
washed or underwent DMSO dilution only (Table 4). We did
not observe differences in early survival after transplantation
of units that were not washed (n ¼ 40; 78% [95% CI, 63% to
89%]) and DMSO dilution only (n ¼ 70; 77% [95% CI, 67%
to 86%]).
Toxicities Associated with Infusion
There were no life-threatening or serious or suspected
serious adverse events as deﬁned by the Food and Drug
Administration’s Safety Reporting Requirements (21 CFR
312.32), reported for any of the transplantations in the cur-
rent analysis. One of the infused units was infected, as
deﬁned by a positive product culture (organism not re-
ported). This patient achieved neutrophil and platelet re-
covery and is alive, 2 years after transplantation.
DISCUSSION
In this study, the ﬁrst of its kind, we explored whether
differences exist in hematopoietic recovery and early sur-
vival by processingmethods at the CBBs. The current analysis
was prompted by the concern that variations in processing
and banking have never been fully studied and that these
practice variations might affect the early outcomes of UCB
transplantation. In a carefully controlled analysis and
adjusting for known patient, disease, and transplantation
characteristics, we identiﬁed 2 banking practices with
adverse effects on early neutrophil recovery (ie, at day 28).
Neutrophil recovery was lower after transplantation of
manually processed UCB units that were plasma reduced
(red blood cell replete) or plasma and red cell depleted
compared with automated methods of processing with
plasma and red cell depletion. Automated processing is
relatively recent, and only 118 UCB units were processed
using automated techniques in this study [21]. Further,
among the manually processed units, neutrophil recovery
was less likely with plasma reduction. Lower rates of
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not translate into higher early overall mortality, implying
advances in supportive care during the early neutropenic
period in part negated its adverse effects on early survival.
Additionally, thawing methods were associated with early
survival. Survival was better when units were washed and
reconstituted in dextran, hespan, or plasmalyte, implying
thawing techniques at transplantation centers may inﬂuence
early survival. The observed adverse effect of thawing tech-
niques at transplantation centers was independent of unit
processing and banking at CBBs; nor was it associated with
hematopoietic recovery. The results of the bedside thaw
approach in 26 transplant recipients and that from the thaw
and dilute approach in 54 patients from single institutions
demonstrated these approaches were safe and with sus-
tained hematopoietic recovery [14,15].
To our knowledge, the current analysis is the ﬁrst to have
compared the 3 approaches to UCB thaw. It is worth noting
that we do not have detailed information on handling and
processing of UCB units at the transplantation centers or
information as to whether the transplantation centers fol-
lowed the recommendations for thawing by the CBB, all of
which may have an effect on survival. With the data avail-
able, it is not possible to recommend 1 approach over
another other than to recommend UCB unit thaw that either
adheres to the recommendations from the CBB or adopt
techniques that have been validated by the institution’s cell
processing laboratory. We did not identiﬁy differences in
hematopoietic recovery or overall survival based on the years
of banking experience, year of collection of UCB unit, storage
condition (vapor versus liquid phase), and the length of time
the UCB unit was stored at the CBB.
Our ﬁndings differ from that reported by others on the
effects of transplantation of UCB units that were plasma
reduced [11]. The report by Chow et al. [11] demonstrated
neutrophil recovery rates higher than reported in the current
analysis. An important difference between that analysis and
the current analysis is that in the former, neutrophil recovery
rates were calculated with the Kaplan-Meier method,
whereas the current analysis used the cumulative incidence
estimator, which considers the competing risk for the event
of interest, ie, death without recovery.
As expected from other studies in the literature, day 100
survival was improved for patients who underwent trans-
plantation in ﬁrst complete remision and for those patients
who underwent transplantation after 2004 [22,23].
Although higher performance status, younger age, and
higher cell dose were associated with improved survival in
other larger studies on single UCB transplantation, these
factors did not affect survival in this current study and were
likely attributed to that fact that we explored factors asso-
ciated with survival within 3 months after transplantation
[24]. The only plausible explanations include the fact that the
current analysis is limited to primarily a pediatric cohort,
with about 80% of patients ages  16 years and that their
performance scores were 90 or 100. Similarly, almost 90% of
patients received UCB units with a TNC dose in excess of
3  107/kg.
The current analysis has several limitations. First, our
analysis is limited to approximately 500 and largely, pedi-
atric, recipients of single unit UCB transplantation and
comprises approximately 10% of UCB units distributed by the
participating CBBs. To allow us to carefully examine for CBB
processing and banking, we limited the cohort to a relatively
homogenous group of patients who received a single UCBunit, which explains the relatively small numbers of trans-
plant recipients in the current analysis; we arbitrarily
assigned CBB practices into 3 broad groups. Second, although
we adjusted for known prognostic factors, there may be
several unknown and unmeasured practices both at CBBs
and transplantation centers that inﬂuenced the outcome.
Third, wewere not able to study storage temperature at CBBs
[25], cell viability, or the cord blood Apgar score [26]. Fourth,
CBBs were surveyed for their banking practice with reliance
on self reporting. All other data were collected on stan-
dardized CIBMTR reporting forms with appropriate data
management manuals and subject to audit.
Despite the limitations, our observations have clinical
relevance. Banking practices are not associated with early
survival, but manual methods of UCB unit processing lower
the odds of neutrophil recovery during the very early post-
transplantation period. Although only 6 CBBs were using
automated processing methods at time of survey about a
year ago, it is possible several CBBs have switched to the
automated methods. These data support selecting an
adequately dosed and HLA-matched or HLA-mismatched
UCB unit that was processed using automated methods
when such a unit is available.
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